INTRODUCTION:
Myeloid cells have emerged as key regulators of cancer growth because of their abundance in the tumor stroma in a broad range of cancers, their association with clinical outcome, and their ability to modulate tumor progression. Most tumor-infiltrating myeloid cells derive from circulating precursors, which are produced in distant tissues, and some tumors amplify myeloid cell activity by skewing hematopoiesis toward the myeloid lineage or increasing myeloid cell populations in the periphery. For example, patients across diverse cancer types can present with elevated levels of myeloid progenitor cells in peripheral blood. Additionally, increased numbers of circulating myeloid cells, such as neutrophils, often correlate with poorer clinical outcome. It is therefore important to consider host changes that occur away from the tumor stroma to more fully understand the biological processes underlying tumor growth.
RATIONALE:
The bone marrow is a tissue of particular interest as it is the main production site for hematopoietic cells corresponding to all circulating blood lineages in the adult. The marrow contains resident cell components, such as osteoblasts, which not only participate in bone maintenance but also regulate hematopoiesis and immune cell fate. However, our understanding of bone dynamics in the context of cancer (growing at sites distant from the local bone microenvironment) and related immune responses remains limited. To address this knowledge gap, we explored whether a common solid cancer-lung adenocarcinoma-remotely affects bone tissue and how this might shape tumorassociated hematopoietic responses and tumor growth.
RESULTS:
We show in different mouse models and in cancer patients (n = 70) that lung adenocarcinomas increase bone stromal activity even in the absence of local metastasis. Animal studies further reveal that the cancer-induced bone phenotype involves bone-resident osteocalcinexpressing (Ocn + ) osteoblastic cells. Ocn + cells affect distant tumor progression because experimentally reducing the number of these cells limits lung tumor growth. Also, Ocn + cells are required for full-fledged tumor infiltration by a distinct subset of neutrophils that are defined by their high expression of the lectin SiglecF (sialic acid-binding immunoglobulinlike lectin F). Compared to other neutrophils, SiglecF high cells express genes associated with cancer-promoting processes, including angiogenesis, myeloid cell differentiation and recruitment, extracellular matrix remodeling, suppression of T cell responses, and tumor cell proliferation and growth. Additionally, SiglecF high neutrophils have increased reactive oxygen species production, promote macrophage differentiation, and boost tumor progression in vivo. We further report that the soluble receptor for advanced glycation end products (sRAGE) is up-regulated in the circulation of tumor-bearing mice and fosters osteoblastic activity and osteoblast-dependent neutrophil maturation in vitro.
CONCLUSION: This study identifies systemic cross-talk between lung tumors and bones: Lung tumors can remotely activate Ocn + osteoblastic cells in bones even in the absence of local metastasis. In turn, these Ocn + cells supply tumors with SiglecF high neutrophils, which foster cancer progression. The findings bear scientific and therapeutic importance because they reveal contributions of the host systemic environment to tumor growth and they position Ocn + cells, SiglecF high neutrophils, and sRAGE as candidate clinical biomarkers and possible intervention points for anticancer therapy.
M
yeloid cells have emerged as key regulators of cancer growth because of their abundance in the tumor stroma in a broad range of cancers, association with patient disease outcome, and ability to modulate tumor progression (1) (2) (3) (4) . Most tumorinfiltrating myeloid cells are continuously replenished by circulating precursors, which are produced in distant tissues (4, 5) , and some tumors amplify myeloid cell activity by skewing hematopoiesis toward the myeloid lineage or increasing myeloid cell populations in the periphery (6) (7) (8) . For example, patients across cancer types present with elevated levels of hematopoietic myeloid progenitor cells in peripheral blood (9) . Additionally, increased numbers of circulating myeloid cells, such as neutrophils, often correlate with poorer clinical outcome (10) (11) (12) . It is therefore important to consider host changes that occur away from the tumor stroma to more fully understand the biological processes underlying tumor growth.
The bone marrow is a tissue of particular interest because it is the main site of hematopoietic cell production for all circulating blood lineages in the adult (13) . The marrow contains resident cell components that not only participate in bone maintenance but also regulate hematopoiesis and immune cell fate, at least at steady state (14) (15) (16) . For example, osteoblasts, which are boneforming cells, were the first bone-resident cells identified to regulate hematopoiesis (13, 14, 17) . However, our understanding of bone dynamics in the context of cancer (at sites distant from the local bone microenvironment) and related immune responses remains limited. To address this knowledge gap, we explored whether a common solid cancer-lung adenocarcinoma-affects bone tissue and how this might shape tumorassociated hematopoietic responses and distant tumor growth.
Lung tumors modulate bone density in mice and patients
To test whether lung tumors disrupt bone homeostatic activity, we initially used a fluorescent bisphosphonate derivative (OsteoSense-750EX) (18) that binds hydroxyapatite minerals in areas of active bone formation and is detectable in vivo by fluorescence-molecular tomography (FMT) (19) . We considered a mouse model of lung adenocarcinoma in which tumors are induced by intratracheal delivery of Adenovirus-Cre (AdCre), which activates oncogenic Kras and deletes the tumor suppressor Trp53 (hereafter referred to as KP; fig. S1 , A to C), and whose growth recapitulates key aspects of the human disease (20) . We also used the KP1.9 tumor cell line, which derives from KP lung tumor nodules and behaves similarly to its autochthonous counterpart (21) , and the Lewis lung carcinoma (LLC) cell line, a commonly used murine lung tumor model. In vivo FMT analysis of the femoral-tibial joint ( fig. S2A ) showed significantly elevated OsteoSense activity in both KP (Fig. 1, A and B) and LLC ( Fig. 1C and fig. S2B ) lung tumor-bearing mice, when compared to tumor-free controls.
Ex vivo analysis of explanted bones from KP tumor-bearing mice further revealed that this activity extended across all compartments analyzed, including the elbow joint, sternum, ribs, vertebrae, and pelvic bone (fig. S2, C to E). Bone metastases have not been reported for mice bearing KP tumors (20) , which we confirmed by histology and polymerase chain reaction (PCR)-based methods (fig. S3, A to E). These studies indicate that lung tumors can disrupt bone stromal activity in the absence of local metastasis.
By using confocal microscopy, we also found increased OsteoSense signal in the sternum ( Fig.  1D and fig. S4A ) and distal femur ( fig. S4B ) of KP1.9 tumor-bearing mice. The signal's location was separate from vasculature and enriched in areas of active bone remodeling, including the edges of sternebrae, which are associated with areas of increased bone in the sternum (Fig. 1D  and fig. S4A ). OsteoSense signal was also found in the metaphysis of the femur, which is an area of active trabecular bone formation adjacent to the growth plate ( fig. S4B ) as well as the epiphysis and diaphysis of the femur ( fig. S4B ).
These data suggested that KP tumors might influence bone microarchitecture. Accordingly, high-resolution microcomputed tomography (mCT) showed increased trabecular bone volume ( Fig. 1E and fig. S5 , A to C) and higher mineral density of distal femoral metaphysis ( fig. S5D ) in mice bearing KP tumors. The same mice also showed more ( fig. S5E ) and thicker ( fig. S5F ) trabeculae and decreased space between those trabeculae ( fig. S5G ). Cortical bone morphology in the femoral mid-diaphysis showed similar tumorinduced phenotypes ( fig. S5H ). Figure S5I includes a complete tabulation of the mCT results.
To investigate the relevance of our findings to human disease, we examined 35 KRAS + non-small cell lung cancer (NSCLC) patients who had undergone noncontrast chest computed tomography (CT) before cancer therapy and did not have osseous metastases . These patients were  matched by age, sex, body mass index, and smoking status to 35 control individuals who did not  have active malignancy or chronic illness and  who did not use medications known to affect  bone metabolism (table S1 ). This analysis revealed significantly higher trabecular bone density in the thoracic vertebrae of KRAS + NSCLC patients compared to controls (Fig. 1F and table S1 ). Similarly, equivalent analysis of 35 KRAS nonmutant NSCLC patients revealed increased bone density compared to their matched controls (Fig. 1G) . Thus, lung tumor-induced changes in bone occur in both mice and humans.
Lung tumor-induced bone alterations involve osteoblasts
The bone phenotypes may be explained by altered osteoblast and/or osteoclast activity (22) . Histological analysis of these cell lineages in the distal femur identified more osteoblasts in KP tumor-bearing mice than in tumor-free controls (Fig. 2, A and B) . Osteoblasts in tumorbearing mice also exhibited features of increased activity, including cuboidal shape and association with osteoids ( Fig. 2A) . Accordingly, the osteoid surface, characterizing newly formed bone, expanded in tumor-bearing mice ( fig. S6A ). By contrast, osteoclast numbers ( fig. S6B ) and eroded bone surfaces ( fig. S6C) were not significantly different in tumor-bearing mice, although there was a trend for lower osteoclast-related indices compared to tumor-free controls.
To trace osteoblastic lineage cells by genetic means, we generated mice that expressed Credriven yellow fluorescent protein (YFP) under the control of the osteoblastic cell reporter osteocalcin (Ocn). Ocn is mainly expressed by mature osteoblasts and constitutes the major noncollagenous protein in the bone (23, 24) . We found that Ocn-YFP + cells expanded in KP tumor-bearing mice when compared to tumorfree controls (Fig. 2C) . Femurs of tumor-bearing mice showed increased mineralized bone and bone formation, as assessed by von Kossa staining ( Fig. 2D ) and dynamic histomorphometry ( Fig. 2E and fig. S7 ).
We next compared the transcriptome of osteocalcin-expressing (Ocn + ) cells from tumorfree and lung cancer-bearing mice to ask whether Ocn + cells in lung cancer-bearing mice acquire unique phenotypes. Specifically, we generated triple transgenic KP-Ocn-GFP (green fluorescent protein) reporter mice (that is, genetically engineered KP mice in which GFP expression is driven by the Ocn promoter) (20, 25) figures show means ± SEM. Statistical significance was calculated using an unpaired t test. **P < 0.01, ***P < 0.001.
overexpression leads to increased trabecular bone mass (26, 27) . Statistical significance was calculated using an unpaired t test. *P < 0.05, **P < 0.01.
We next considered whether controlled KP tumor progression in Ocn + cell-reduced mice involves the altered neutrophil response. In this scenario, removing neutrophils should delay growth of the primary tumor even in the presence of Ocn + cells. Accordingly, targeting neutrophils with depleting antibodies (Fig. 3D and  fig. S14 , A and B) significantly suppressed KP lung tumor progression in Ocn + cell-sufficient mice, as defined by longitudinal and noninvasive mCT monitoring of lung tumor nodules (Fig. 3D) .
To assess Ocn + cells' impact on the tumorinduced systemic neutrophil response, we compared the number of circulating neutrophils in the presence or absence of KP lung tumors when Ocn + cells were depleted or not. We found that the presence of KP tumors was associated with a significant increase in the number of (CD11b + Ly-6G + ) neutrophils in the blood (Fig. 3E) To further test this idea, we assessed tumor microenvironments when the circulatory systems of mice were joined by parabiosis. We found that joining osteoblast-reduced mice to osteoblastsufficient mice increased tumor-infiltrating CD11b + Ly-6G + neutrophil numbers in the former by ∼ two-fold (Fig. 3F ). These neutrophil numbers were comparable to those seen in control (osteoblast-sufficient, nonparabiosed) mice [2.2 ± 0.4-fold; P = n.s. (not significant)]. Tumors in osteoblast-reduced mice grew faster when joined to osteoblast-sufficient parabionts (Fig. 3F ) and similarly to tumors in control (osteoblast-sufficient, nonparabiosed) mice (lung weights, 557.1 ± 68.3 and 560.6 ± 29.2 mg, respectively; P = n.s.). Thus, both tumor neutrophil counts and tumor progression were restored in osteoblast-reduced mice when parabiosed to Ocn + cell-sufficient mice. Combined, these data not only show that Ocn + cells contribute tumor-infiltrating neutrophils but also suggest that these cells display tumor-promoting functions. Cre;Dtr mice (depicted in black). Right: Lung weight of the same mice (n = 4 to 6 mice per group). Statistical significance was calculated using an unpaired t test. All figures show means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
Ocn
immunoglobulin-like lectin F) (Fig. 4A ). The SiglecF low subset appeared in high numbers in healthy lungs and expanded only slightly in lungs from tumor-bearing mice; by contrast, the SiglecF high subset was rare in the healthy tissue but expanded~70-fold in tumor-bearing lungs (Fig. 4, A shown as fold change relative to control mice. All figures show means ± SEM, and significance values were calculated using multiple t tests. *P < 0.05, **P < 0.01, ****P < 0.0001. Lin., Lineage.
T-SiglecF high cells selectively up-regulated the expression of genes associated with tumorpromoting processes (Fig. 5B, fig. S19D , and table S5), including angiogenesis (Vegfa, Hif1a, and Sema4d), myeloid cell differentiation and recruitment (Csf1, Ccl3, and Mif), extracellular matrix remodeling (Adamdec1, Adam17, and various cathepsins), suppression of T cell responses (Cd274/PDL1, Fcgr2b, and Havcr2), and tumor cell proliferation and growth (Tnf, Tgfb1, and Il1a). T-SiglecF high cells also showed decreased expression of genes involved in cytotoxicity (Cd244, Itgal, and Fas) (Fig. 5B) . Other genes overexpressed in T-SiglecF high cells included the endoplasmic reticulum stress-response gene and transcription factor Xbp1 and the shortchain fatty acid receptor Ffar2 (Fig. 5A) ; Xbp1 impairs myeloid antitumor functions (30) and positively regulates Ffar2 expression (31) . Gene set enrichment analysis indicated up-regulation of genes involved in oxidative phosphorylation, fatty acid metabolism, and glycolysis, suggesting that T-SiglecF high cells undergo a metabolic switch ( fig. S20A ). Genes involved in Myc signaling and E2F gene targets were also overexpressed, suggesting that T-SiglecF high cells are more proliferative and resistant to apoptosis ( fig. S20A ). Together, these findings suggest that SiglecF high neutrophils undergo metabolic changes in the tumor microenvironment and are poised to support tumor-promoting functions, including tumor angiogenesis, tumor cell proliferation, extracellular matrix remodeling, and immunosuppressive myeloid cell recruitment.
Tumor-infiltrating neutrophils are replenished by circulating cells. We thus explored whether differentiated SiglecF high neutrophils already exist in the blood of tumor-bearing mice. Specifically, we sorted CD45 + CD11b + Ly-6G + neutrophils from the blood of either tumor-free or lung tumor-bearing mice and assessed the expression of several genes that we identified to be selectively up-regulated by tumor-infiltrating SiglecF high neutrophils. This analysis revealed increased expression of transcripts corresponding to SiglecF, Xbp1, and Clec4n (and, to a lesser extent, to Ltc4s) in circulating neutrophils from tumor-bearing mice ( fig. S21A ). In contrast, the expression of Vegfa and Clec5a was unchanged, and flow cytometry analysis showed comparable expression of SiglecF high -associated cell surface proteins ( fig. S21B ). These findings suggest that at least some circulating neutrophils acquire molecular features of SiglecF high neutrophils before arrival at the tumor site. However, the acquisition of full-fledged SiglecF high neutrophil phenotypes occurs only after the cells have reached their destination tissue (which likely limits execution of the cells' effector functions to that site). , and HSiglecF low cells) to produce reactive oxygen species (ROS), which drive diverse protumorigenic inflammatory responses (6, 32, 33) . To this end, we measured intracellular ROS using an imaging probe that becomes fluorescent upon activation by ROS (6) . SiglecF high neutrophils showed increased ROS activity compared to SiglecF low neutrophils in tumor or tumor-free tissue (Fig. 5C ), indicating that ROS activity provided by neutrophils is contributed mainly by the SiglecF high subset.
Second, we assessed the ability of SiglecF high neutrophils to support other tumor-promoting myeloid cells. The neutrophil RNA-seq analysis (Fig. 5A ) revealed that T-SiglecF high neutrophils expressed high levels of the mRNA encoding colony-stimulating factor-1 (CSF-1), which is critical for the differentiation of macrophages from monocytes. In addition, monocyte-derived tumor-associated macrophages drive KP tumor growth (8 35) and asked whether the expression of a SiglecF high neutrophil gene signature was associated with disease outcome in patients with lung adenocarcinoma. A Cox proportional hazards model, controlling for confounding variables, revealed a statistically significant (P = 0.0017) association of the SiglecF high neutrophil signature with worse patient survival (Fig. 5G, fig. S22 , and tables S7 and S8). In contrast, the SiglecF low neutrophil signature did not associate with disease outcome in lung cancer patients. The survival of the top 25% versus bottom 25% of SiglecF high and SiglecF low neutrophil signature expressers is shown in Kaplan-Meier plots (Fig. 5G ). If these results are confirmed in future studies of independent cohorts of lung adenocarcinoma patients, the T-SiglecF high gene signature may prove to be a valuable biomarker of poorer prognosis.
sRAGE contributes to the osteoblastinduced neutrophil response
The activation of bone marrow-resident cells by distant lung tumors likely involves tumor-induced signals that act over extended distances and stimulate Ocn + osteoblasts. To begin to address the underlying molecular and cellular mechanisms, we first set up in vitro experiments to define whether the blood of lung tumor-bearing mice contains factors that increase osteoblastic lineage cell activity. We collected serum from either lung tumor-bearing or tumor-free mice and added the serum to bone marrow cells cultured under osteogenic conditions. We then quantified the number of osteoblastic colonies measured by alkaline phosphatase enzymatic staining, as a proxy for osteoblastic activity. As shown in Fig. 6A , serum from tumor-bearing animals significantly increased the number of osteoblastic colonies compared to serum from tumor-free mice. Thus, blood components from tumor-bearing mice are sufficient to promote osteoblastic lineage cells.
To identify specific serum factors that contribute to increased osteoblast activity, we used a protein array to quantify 111 cytokines and growth factors in the blood collected from tumor-bearing or tumor-free mice. We found that the concentration of most of the factors tested was similar in tumor-bearing and tumor-free mice [including the myeloid growth factors G-CSF (granulocyte CSF), GM-CSF (granulocyte-macrophage CSF), and M-CSF (macrophage CSF)], whereas some factors (for example, C1qR1, CCL21, and complement factor D) were slightly enriched in tumorbearing mice. Notably, the receptor for advanced glycation end products (RAGE) was up-regulated about twofold in the blood of tumor-bearing mice when compared to tumor-free mice (Fig. 6B and  fig. S23, A and B) . We confirmed this finding using an independent enzyme-linked immunosorbent assay ( fig. S23C ).
Various ligands can activate membranebound RAGE to trigger proinflammatory cascades, a process that has been implicated in several diseases, including diabetes, Alzheimer's disease, and cancer. The circulating form of RAGE, referred to as soluble RAGE (sRAGE), can prevent the binding of ligands, including Engblom et al., Science 358, eaal5081 (2017) 1 December 2017 advanced glycation end products, to the RAGE receptor (36) . Previous studies have connected sRAGE and RAGE ligands to bone regulation (37) (38) (39) . To test the possibility that sRAGE contributes at least in part to increasing osteoblastic activity, we repeated the in vitro osteoblast culture experiment described above, but this time, we specifically asked whether supplementing serum from tumor-free mice with sRAGE was sufficient to stimulate osteoblast activation. This experimental condition significantly increased osteoblastic colony-forming units when compared to control conditions (Fig. 6C) . Finally, we investigated whether sRAGE could stimulate bone marrow neutrophil maturation and whether this process involved stromal osteoblastic cells. Because developing bone marrow neutrophils require up-regulation of CXCR2 expression for release into blood (1), we tested neutrophil expression of this chemokine receptor. To this end, we cultured Lin − c-Kit + bone marrow hematopoietic cells with or without the ST2 preosteoblastic cell line and in the presence of increasing doses of exogenous sRAGE (Fig. 6D) . This experiment indicated that the presence of sRAGE increases CXCR2 expression on developing neutrophils. Furthermore, we found that CXCR2 Means ± SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical values were calculated using one-way ANOVA (C and E) or two-way ANOVA (F). H, Healthy; T, Tumor.
expression increased only in the presence of bone marrow stromal cells. These preliminary data support the notion that tumor-associated factors can stimulate osteoblastic cells, which in turn regulate immune responses, and suggest sRAGE as an interesting candidate for further investigation.
Discussion
This study identifies systemic cross-talk between lung tumors and bones: Lung adenocarcinomas can remotely activate Ocn + osteoblasts in bones even in the absence of local metastasis. In turn, these osteoblasts supply tumors with SiglecF high neutrophils, which foster cancer progression. The tumor-promoting functions of SiglecF high neutrophils align with previous experimental data showing that neutrophils can promote cancer in various animal models (6, (40) (41) (42) (43) (44) (45) . The findings also align with human studies, which indicate that a high neutrophil-to-lymphocyte ratio in blood is associated with adverse overall survival in many solid cancers, including that of the lung (10) , and that lung adenocarcinoma infiltration by neutrophils is strongly linked to poorer clinical outcome (46) . Both single-cell transcriptomics and functional studies suggest that SiglecF high neutrophils, but not their SiglecF low counterparts, promote primary tumor growth. These data support the idea that tumor-infiltrating neutrophil populations encompass cell subsets with heterogeneous functions (1) and suggest new ways to interrogate the neutrophil response to cancer. The phenotype exhibited by SiglecF high neutrophils resembles at least in part that of granulocytic myeloid-derived suppressor cells (MDSCs) (47) . For example, both granulocytic MDSCs and SiglecF high neutrophils express the CD11b and Ly-6G surface markers, up-regulate proangiogenic factors (for example, Vegfa), and produce high levels of ROS (47) .
Osteoblastic-lineage cells are mostly known for their role in the control of bone formation (22, 48, 49) , but increasing evidence indicates that these cells can also regulate hematopoiesis (17, 50) with reported impacts on both B cell (51-54) and T cell (52, 55) production at steady state. Also, genetic perturbations of osteoblastlineage cells deregulate myelopoiesis and can instigate myeloid hematopoietic malignancies (56) (57) (58) . Here, we further report that osteoblastic cells can control tumor-infiltrating SiglecF high neutrophils, that is, a discrete immune cell subset of the tumor microenvironment. We did not find evidence that osteoblastic cells control tumorinfiltrating B or T cells, although it is possible that osteoblast-mediated regulation of lymphocytes or other immune cells occurs in other cancer types. Furthermore, the bone marrow is composed of many different resident cell populations including adipocytes, endothelial cells, hematopoietic cells, and neurons, which, together with osteoblasts, form a complex network that is critical to the production, maturation, and egress of hematopoietic populations (13) . It is conceivable that some cancers affect multiple bone-resident cell populations, which in turn regulate distinct tumor-associated immune events. The study of additional bone marrow-resident cells, for example, with Cre-based models (13) , may help to capture more fully the complexities of systemic tumor-associated host responses. Additionally, better understanding how lung tumors activate osteoblasts will require further study. Beside the effects of sRAGE identified in this study, it is possible that tumor-bone interactions involve additional components, which remain to be identified.
In accordance with amplified osteoblastic activity in tumor-bearing mice, we observed increased bone density in lung adenocarcinoma patients. This contrasts with the decrease in bone density that is known to occur in patients with some cancer types [for example, those with parathyroid hormone-related protein (PTHrP)-secreting tumors (59)] or more broadly in cancer patients after certain anticancer therapies (60, 61) . Here, we focused on patients before cancer therapy, and we excluded individuals with chronic conditions (for example, rheumatoid arthritis), medication use (for example, glucocorticoids, bisphosphonates, and previous cancer treatment), paraneoplastic syndromes, and osseous metastases, because these variables can all influence bone density. Because cancer cachexia or smoking can also lead to bone loss, we carefully matched our lung cancer patients to control individuals with similar body mass index, age, and smoking history. Furthermore, because most lung cancer patients undergo chest CT scans with the administration of intravenous contrast, which can artificially increase bone density measurements (62), we limited our analysis to noncontrast CT scans. Our findings, based on the analysis of 140 individuals, indicate that in NSCLC patients, the primary tumor alters bone metabolism, resulting in increased bone density. It will be important to investigate bone parameters in more patients and in various clinical conditions, because the systemic manifestation of cancer is complex and may vary depending on disease stage, tumor type, and the tumor's secretory profile. This study underscores the importance of studying cancer as a systemic disease. Interrogating tumor-associated host responses through this lens should be important to fully address fundamental mechanisms of tumor immunity and effects of cancer therapies. Specifically, considering immune cells as critical therapeutic targets, it will be relevant to broadly investigate hematopoietic organs distant from the primary tumor to uncover ways in which cellular and molecular components at those sites control hematopoietic cell production, maturation, and activation in cancer and how these parameters can be manipulated. Given their involvement in shaping tumor progression, our study posits bone marrow-resident Ocn + cells and SiglecF high neutrophils as relevant clinical biomarkers and candidate vantage points for anticancer therapy.
Materials and methods Mice
Kras LSL-G12D/WT ;p53 Flox/Flox (referred to as KP) mice were used as a conditional mouse model of NSCLC (20) and bred in our laboratory in the C57BL/6 background or in the laboratory of Dr. Meylan. To track and deplete osteoblastic lineage cells by genetic means, we generated mice that expressed Cre-driven yellow fluorescent protein (YFP) under the control of the osteoblastic cell reporter osteocalcin (Ocn) (49, 63, 64 Gfp-topaz (C57BL6/Tg(BGLAP-Topaz)1Rowe/J) mice (25) . Cd11c
Dtr mice (B6.FVB-Tg(Itgax-DTR/ EGFP)57Lan/J) were obtained from Jackson Laboratory. Cd169
Dtr transgenic mice (Siglec1 tm1(HBEGF)Mtka ) were kindly provided by the Riken Institute (Japan). Wild type and CD45.1 C57BL/6 mice were purchased from Jackson Laboratory. All animal experiments were performed according to approved IACUC guidelines, except experiments in KP mice for anti-Gr-1 antibody (Ab) depletion that were approved by the Veterinary Authority of the Canton de Vaud, Switzerland (license number VD2391) and the Réseau des animaleries lémaniques (RESAL) competent ethic committee.
Following primers were used for genotyping Ocn
Cre;Dtr/Yfp and Ocn Gfp mice: iDTR = WSS-F: 5′-GGCTACTGCTGACTCTCAACATT-3′; DTR-R: TCATGGTGGCGAATTCGAT Cre = OcnCre-F: CAA ATA GCC CTG GCA GAT TC; OcnCre-R: TGA TAC AAG GGA CAT CTT CC GFP (Jackson Laboratory) = oIMR0872: TTC ATC TGC ACC ACC G; oIMR1416: TTG AAG AAG ATG GTG CG
Tumor models
Adenovirus-Cre (AdCre) was delivered intratracheally (i.t.) to KP mice as previously described (20, 21) . Mice were analyzed for bone or tumor phenotypes 12-14 weeks post-tumor initiation. Tumor burden was scored by measuring postmortem lung weight and by histological analyses of lung tissue using hematoxylin and eosin (H&E) stainings. For some experiments microcomputed tomography (mCT) was used to monitor tumor burden in the lung. The lung adenocarcinoma cell line KP1.9 was used to induce lung tumors in male wild-type C57BL/6, Ocn
Cre;Dtr or Ocn Cre;Yfp mice via intravenous (i.v.) tail vein injection (0.25 × 10 6 cells in 100 ml PBS). In some osteoblast depletion experiments, mice were killed before DT treatment to quantify the average lung weight (as a proxy for tumor burden). This number was used to calculate the delta lung weight post DT treatment. Male mice with KP1.9 tumors were typically euthanized between 28-41 days after tumor cell injection. Cells of the Lewis lung cancer line (LLC, 1.5 × 10 6 cells in 150 ml PBS) were injected i.v. into wild-type C57BL/6 mice and the mice were euthanized 32 days post-tumor cell injection. Diphtheria toxin (DT) was used to deplete Ocn + cells in Ocn Cre;Dtr and Ocn
Cre;Dtr/Yfp mice; for the detailed depletion protocol see section: In vivo osteoblast depletion.
Cell lines
The KP1.9 cell line, derived from lung tumor nodules of a C57BL/6 KP mouse, was kindly provided by Dr. Zippelius (University Hospital Basel, Switzerland). GFP-positive KP1.9 cells (KP-GFP cell line) were established in our laboratory. The LLC cell line was obtained from ATCC and ST2 cells were kindly provided by Marc Wein (MGH). All cell lines were maintained in Iscove's DMEM media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
Patient bone density measurements
The study was conducted using IRB approval (2016P000394/MGH) and complied with HIPAA guidelines with exemption status for individual informed consent. A retrospective search was performed to identify patients with non-small cell lung cancer (NSCLC) who were KRAS positive and KRAS negative, and who had undergone non-contrast chest CT prior to therapy at MGH between 2011 and 2017. Patients with osseous metastases, paraneoplastic syndrome or therapy prior to or at time of chest CT were excluded. Control subjects (referred to as control patients) who had undergone non-contrast chest CT using the same imaging protocols as the patient group were identified and 1:1 matched for sex, age within ±2 years, BMI within ±2 kg/m 2 , and smoking (pack-years). Potential controls with active malignancy, significant chronic illness or medication use known to affect bone metabolism were excluded. Trabecular bone density was determined from non-contrast chest CT (16-or 64-MDCT scanner Biograph 16 or 64, Siemens Healthcare; or Discovery CT750HD, GE Healthcare) using an axial slice thickness of 2.5 or 5 mm, 120 kVp and 11-40 mAs. Scans were then reviewed offline on an IMPAX workstation (AGFA Diagnostic Software, version 4, Afga). Circular regions of interest (exemplarily shown in Figure  1F ) within trabecular bone of the T6, T8, T10 and T12 vertebral bodies were placed manually, avoiding cortical bone and posterior veins. The mean trabecular bone density of each vertebral body in Hounsfield Units (HU) was determined and an average thoracic trabecular bone density of the four vertebral bodies was calculated.
Fluorescence molecular tomography (FMT)
OsteoSense-750EX (18) was injected retro-orbitally (4nmol/100ml, Perkin Elmer) according to manufacturer's instructions. The mice (for in vivo study) or cleaned bones (for ex vivo investigation) were imaged with FMT no earlier than 4 h and no later than 24 h post OsteoSense injection using an FMT imaging system (VisEn Medical). For in vivo imaging, hair from hind legs and lower abdomen were removed by shaving and chemical depilation. Mice were anaesthetized using isoflurane during the entire scanning procedure. The positioning of the mice relative to the detector were kept consistent throughout the experiments and groups. Detected OsteoSense signal in the femoral-tibial joint (region of interest, ROI) was analyzed using TrueQuant software and normalized against age and sex-matched control values.
Micro-computed tomography (mCT) for lung tumor measurements
Lung tumor volumes were received through repeated mCT measurements and pre-versus posttreatment measurements calculated. Mice were anaesthetized using isoflurane during the entire scanning procedure. Lungs were imaged with a CT (Quantum FX, PerkinElmer) at a 50 mm voxel size, with retrospective respiratory gating. Individual tumor volumes were measured and calculated using the Analyze software (PerkinElmer). Fold change in tumor volume was calculated by dividing post-treatment lung tumor measurements by pretreatment values.
Micro-computed tomography (mCT) for bone microarchitecture
Femurs from KP1.9 tumor-bearing versus ageand sex matched tumor-free controls were dissected out, cleaned, fixed in 10% formalin for 24 h, washed in PBS and transferred to 70% ethanol (EtOH) prior to mCT analysis. Trabecular Engblom et al., Science 358, eaal5081 (2017) 1 December 2017 bone microarchitecture and cortical bone morphology in the distal femoral metaphysis and middiaphysis, respectively, were quantified using a high-resolution desktop micro-tomographic imaging system (mCT40, Scanco Medical AG). The scans were performed using the following settings: 10mm 3 isotropic voxel size, 70 kVp peak x-ray tube intensity, 114 mA x-ray tube current, 200 ms integration time, and were subjected to Gaussian filtration and segmentation. Image acquisition and analysis protocols were performed according to mCT guidelines for the assessment of bone microstructure in rodents (65) . Trabecular bone was analyzed in a region (1500 mm; 150 transverse slices) extending proximally from 200 mm above the peak of the distal growth plate. A threshold of 339 mgHA/cm 3 was used to segment trabecular bone from soft-tissue and then, trabecular bone volume fraction (BV/TV, %), trabecular thickness (Tb.Th, mm), trabecular number (Tb.N, 1/mm), trabecular separation (Tb.Sp, mm), and trabecular bone mineral density (Tb.BMD, mgHA/ccm) were measured using the Scanco Evaluation program trabecular morphology script. Cortical bone was evaluated in a 500 mm long (50 transverse slices) region at the femoral mid-diaphysis and was segmented using a threshold of 700 mgHA/cm 3 and then analyzed using the Scanco mid-shaft evaluation script to measure total cross-sectional area (Tt.Ar, mm 2 ), cortical bone area (Ct.Ar, mm 
Histology and immunohistochemistry (IHC)
For histological analysis of tumor burden in mice, lung tissues and femurs were harvested, formaldehyde-fixed and paraffin-embedded following standard procedures and consecutive sections were prepared. Lung tissue sections were stained with H&E to define tumor tissue areas in the lung as described earlier (21) .
IHC on mouse tissue sections was performed as previously described (21) . Briefly, mouse lung and bone sections were prepared using a Leica RM2255 rotary microtome (Leica Biosystems), dried at 60°C for 1 h, dewaxed and rehydrated before heat-induced epitoperetrieval (HIER) prior to immunostaining. The sections were incubated in 10mM Tris (pH9.0) or 10mM sodiumcitrate (pH6.0) buffered solution containing 0.05% Tween and, depending on the Ab used, if needed heated at 120°C for 2 min using a pressure cooker. To obtain consistent and reliable staining the LabVision Autostainer 360 (Thermo Fisher Scientific) was used. The sections were pretreated using BLOXALL endogenous enzyme blocking solution (Vector Laboratories) for 10 min to destroy all endogenous peroxidase activity. After blocking with normal goat serum, the sections were incubated with rat anti-mouse Ly-6G (clone 1A8, Biolegend) or anti-mouse osteocalcin (clone M-15, Santa Cruz) monoclonal Abs (mAbs) for 1 h followed by several washes and secondary ImmPRESS polymer detection system (Vector Laboratories) according to the manufacturer's protocol. DAB Quanto (Thermo Fisher Scientific) was applied as substrate and hematoxylin used as counterstain.
Prior to preparation of bone tissue sections, femurs were harvested and cleaned, fixed for 24 h in 10% formalin, washed in PBS and transferred to 70% EtOH. The samples were then decalcified in 14% EDTA for up to two weeks and stored in 70% EtOH until paraffin embedding.
For anti-SiglecF stainings (rat anti-mouse Siglec-F mAb, clone E50-2440, BD Pharmingen), IHC on murine lung tissue of KP tumor-bearing or tumor-free mice was performed on frozen tissue sections. Spleen tissue sections were prepared for reference positive-control stainings. Frozen tissue sections were generated as described before (21), air-dried and fixed in acetone (−20°C) for 10 min. The sections were rehydrated and treated as described above, but without HIER.
For histological evaluation of tumor metastases (femur), 10 regions of interest (n = 8) on paraffinembedded decalcified H&E-stained femur sections were defined at 20x and blindly scored for the presence or absence of tumor cell clusters. Positive control evaluations were done on histological sections from KP tumor-bearing lungs. For all histological sections, image documentation was performed using the NanoZoomer 2.0-RS slide scanner system (Hamamatsu).
Bone histomorphometry
Bone histomorphometric analysis was performed on femurs from KP1.9 tumor-bearing or age and sex-matched tumor-free controls as previously described (66) . In brief, calcein (20 mg/kg; Sigma) and demeclocycline (50 mg/kg, Sigma) were injected at 9 days and 2 days prior to animal euthanasia, respectively. Dissected, cleaned, formalin-fixed (10%, 24 h) femurs were washed in PBS and transferred to 70% EtOH. Fixed nondecalcified femurs were dehydrated (graded ethanol) and subsequently infiltrated and embedded in methylmethacrylate. Longitudinal sections (5 mM) were cut using a microtome (RM2255, Leica) and stained with Goldner's Trichrome for measurements of cellular parameters and by the method of von Kossa (67) to evaluate bone mineralization. Dynamic bone parameters were evaluated on unstained sections by measuring the extent and the distance between double labels using the Osteomeasure analyzing system (Osteometrics Inc.). Measurements were made in the area 200 mm below the growth plate. Quantification of bone parameters was done in a blinded manner. The structural, dynamic and cellular parameters were evaluated using standardized guidelines (68) .
Confocal microscopy
Confocal microscopy was performed based on a previously published protocol (69) . The mice were injected with OsteoSense retro-orbitally to label bone (<24 h before mice were sacrificed) and with fluorescently conjugated mAbs (anti-CD31 (clone MEC13.3, Biolegend), anti-CD144 (clone BV13, Biolegend), anti-Sca1 (clone D7, eBioscience)) 30 min prior to euthanasia via cardiac perfusion with PBS and subsequent 4% methanol-free paraformaldehyde (Alfa Aesar). After fixation, the femurs or sternums were quickly dissected out, cleaned of tissue and cut for imaging. In brief, sternum marrow was exposed by cutting longitudinally along the bone and subsequently scanned at 10x (3-4 partially overlapping field of views). Femurs were OCT embedded, frozen at −80°C (>1 h), and marrow tissue was exposed using a cryostat. Z-stack images from femur and sternum were immediately acquired at 2-5 mM steps (Olympus IV100 confocal microscope) and analyzed in FIJI (ImageJ). Noninjected controls or non-fluorescent mice were used as staining controls.
In vivo Gr-1 + cell depletion
Twelve-to-fourteen week-old KP mice were infected i.t. with 1500 Cre-active lentiviral units using a protocol described earlier (20) . KP mice bearing well-established tumors (identified by mCT) were treated 20 weeks after tumor initiation with anti-Gr-1 mAb (10 mg/kg, clone RB6-8C5, BioXcell) intraperitoneally (i.p.) three times per week for 2 weeks. Neutrophil depletion was validated by tail-vein blood sampling at day 7 followed by flow cytometry analyses of SSC hi Ly-6G + circulating cells. Control mice were injected with IgG control mAb (10 mg/kg, clone 2A3, Jackson Immunoresearch). At the end of the experiment tumor-bearing lungs were collected and single-cell suspensions were obtained using the GentleMACS tissue octo dissociator (Miltenyi) and an enzymatic digestion mix composed of DMEM, 0.02 mg/ml DNAse I (Sigma) and 1 mg/ml collagenase (Sigma) applied for 35 min at 37°C. Cells were washed with medium then resuspended in PBS supplemented by 2% FBS and 0.5mM EDTA. To obtain single-cell suspensions, cells were passed through 70 mm cell strainer. Cell number was determined and Ly-6G-FITC, clone RB6-8C5; anti-CD11b-BV711, clone M1/70; anti-Ly-6C-AlexaFluor700, clone HK1.4; anti-CD11c-BV450, clone N418 and anti-CD45-PerCP, clone 30-F11; all from Biolegend) was performed on ice or a 4°C in PBS supplemented with 2% FBS and 0.5mM EDTA for 15 min. All acquisitions were performed using the LSRII SORP (BD), a 5-laser and 18-detector analyzer at the EPFL Flow Cytometry Core Facility. Data analyses were performed using FlowJo X (FlowJo LLC).
In vivo osteoblast depletion

Ocn
Cre;Dtr
, Ocn
Cre;Dtr/Yfp and control mice lacking either transgene were treated i.p. with DT (100 ml; 20 mg/kg, Sigma-Aldrich) every other day for 9 days with a total of five injections per mouse. In some experiments, osteoblast depletion was performed for 3 consecutive days using DT. For both DT treatment protocols, osteoblast depletion was verified. Body weight was monitored to control for DT-induced toxicity. Osteoblast depletion was verified using histological evaluation of femurs, IHC for osteocalcin and ex vivo whole mount immunofluorescence of Ocn
Cre;Dtr/Yfp mice. Performing in vitro DT titration studies and in vivo cellular stainings using flow cytometry, we ensured that the used DT concentration did not effect the viability of hematopoietic cells in this murine model.
In vivo NK cell depletion
NK cells were depleted in tumor-bearing Ocn
Cre;Dtr or control mice performing i.p. injections of anti-NK1.1 Ab (clone PK136, BioXcell, 200mg/mouse, i.p.) every fourth day. The detailed treatment schema is outlined in fig. S12A . NK cell mAb depletion in osteoblast-reduced tumor-bearing mice was evaluated using flow cytometry and was efficient in depleting lung NK cells (defined as CD49b + NKp46 + cells since the NK1.1 epitope may be masked by the depleting mAb).
In vitro assay to test potential DT-mediated direct effects on hematopoietic cells
Splenocytes from WT, Cd11c
Dtr mice, or Ocn
Cre;Dtr mice were harvested by gently meshing a spleen through a 40 mm filter. The cells were washed, plated in medium (RPMI, 10% FBS, 1% P/S) and treated with 0, 1, 10, 100, 1000 ng/ml of DT. Cells were harvested after 20 h of incubation at 37°C and stained with mAbs for flow cytometry, see section on flow cytometry for staining procedure.
Parabiosis
In some experiments, parabiosis was used to study the contribution of circulating cells to osteoblast-controlled tumor-infiltrating immune cells. The experimental procedure was performed as previously described (70) . In brief, one week post-tumor injection, lung tumor-bearing Ocn
Cre;Dtr mice were parabiosed to Ocn Cre;Dtr or control mice (lacking either transgene). Both types of parabionts were treated with DT following the procedure described in section: In vivo osteoblast depletion.
Neutrophil single cell RNA-seq Single-cell RNA sequencing (scRNA-Seq) data were obtained from CD45 + cells collected from either tumor-free or KP tumor-bearing lungs from two independent experimental replicates using droplet microfluidic barcoding technology (inDrops) as previously described (71, 72) . To identify single cell expression profiles corresponding to neutrophils among other CD45 + cells, we applied a naive Bayes classifier utilizing immune cell gene expression profiles from the Immgen consortium (73) . Data from the isolated cell transcriptomes is provided in table S2. Neutrophil transcriptomes were further divided into SiglecF high and SiglecF low cells as follows. Due to the limited sensitivity of scRNA-Seq at the singlecell level, we classified cells based on a composite SiglecF expression score S, among granulocytes (n = 6,020 cells). For each single cell k, we de- We accounted for multiple hypothesis testing with a false discovery rate of 5% using the Benjamini-Hochberg procedure (74) . To be considered for differential gene expression analysis, genes had to be expressed at least by 5% of cells in at least one of the two groups of cells compared. Significantly differentially expressed genes with an absolute fold-change of 2 were selected for further analysis. Genes judged as significant by the permutation test but with a p-value less than the specified accuracy of the permutation test were assigned an approximate p value using a t-test assuming unequal variances for representation on volcano plots.
For gene set enrichment analysis (75, 76) , we performed the same pre-filtering as for DGE analysis: only genes expressed by at least 5% of cells in at least on the two groups in a comparison were considered. Then we used the GSEA PreRanked tool (75, 76) on genes ranked by log2 (fold-change) and considered gene sets that were enriched based on an FDR of 25%.
Osteoblast low-input bulk RNA-seq
KP-Ocn
Gfp mice were infected with Ad-Cre i.t. and euthanized when high tumor burden was detectable (at 14 weeks post AdCre). All bones were harvested, cleaned and pooled from each single mouse. The bones were crushed gently and the released cells were collected (fraction 1). Red blood cells were lysed using ACK buffer (Lonza) and cells were depleted of mature cells using the lin-depletion kit (Stem cell technologies). In parallel, the bone fragments (fraction 2) were cut finely with scissors, filtered through a 70uM cell strainer (BD), digested for 1h at 37°C (0.25% collagenase type I (Worthington Biochemical Corporation) in FBS), washed and pooled with fraction 1. Ocn-expressing cells were FACS sorted (FACSAria) based on the following parameters:
Approximately 2000 cells were sorted per mouse into Trizol and frozen at −80°C. RNA was isolated using a Trizol extraction protocol according to the Immgen standard www.immgen.org/Protocols/Total%20RNA% 20Extraction%20with%20Trizol.pdf.
Libraries were made following the protocol by Meredith et al. (77) . RNA was reverse transcribed using ArrayScript (Ambion) using a specific primer containing T7 promoter, the 5′ TruSeq Illumina adapter, a 8-positions with random nucleotide assignment as a unique molecular identifier (UMI), and a oligo-dT sequence. Secondstrand synthesis was performed using the mRNA Second strand synthesis module (NEBNext #E6111L). After cDNA size selection using AMPure XP beads (0.8x and 1x, BeckmanCoulter-A63987), the product was amplified via in vitro transcription (MEGAshortscript, Invitrogen) for 12 hours and then fragmented (Magnesium RNA Fragmentation Module, New England Biolabs). 3′ indexing adaptor was ligated (truncated T4 RNA ligase 2 -Enzymatics), reverse-transcribed (Superscript II, Invitrogen), and amplified by PCR for 18 cycles (HiFi hotstart PCR kit, Kapa). cDNA cleanup and size selection were performed on AMPure XP beads. Libraries were quantitated by BioAnalyzer using the Agilent High Sensitivity DNA Kit (Agilent 5067-4626) and qPCR using Kapa library quantification kits, and sequenced on a MiSeq (nano kit) and HiSeq 2500 (rapid mode).
Raw sequencing reads were processed using custom scripts. Read 1 contains the transcript sequence, Read 2 the UMIs. Raw reads were first trimmed using the FASTX-Tollkit v0.0.13 (fastx_trimmer -Q 33) (78). Read 2 was trimmed in order to extract the UMI (5-12bp), and Read 1 was trimmed to 30bp eliminate a potential oligo-dT sequence. Reads were filtered for quality (more than 80% of the sequence having a Sanger Phred+33 quality score > 33) using fastq_quality_filter -v -Q 33 -q 20 -p 80. Mapping was performed with Tophat2 to the mm10 mouse transcriptome (79) keeping the strand information with the following options: tophat -p 2-library-type fr-firststrand -read-mismatches 5 -read-gap-length 5 -readedit-dist 5 -nocoverage-search -segment-length 15 -transcriptome-index. Reads mapping at multiple positions were discarded using samtools flag 256 (80) . Duplicated mapping reads were filtered out using the UMIs with custom R scripts as follows. Reads were first assigned to genes. For each gene, only reads with distinct UMIs were kept. To take into account mutations in UMIs, distinct UMIs but with a Hamming distance of 1 were also collapsed to 1 read. Samples were normalized with DESeq using the estimateSizeFactors Engblom et al., Science 358, eaal5081 (2017) 1 December 2017 function (81) . Multiplot studio was used to define differentially expressed genes in Ocn + cells between tumor-bearing and tumor free mice ( p < 0.05). Osteoblast RNA-seq data has been deposited under accession number GSE104294.
Survival analysis of lung adenocarcinoma patients
Analyses were performed using tumor microarray data and survival outcome in lung adenocarcinoma patients. Raw microarray CEL files along with patient annotations were obtained from two sources: 1) GSE68465 (34) and 2) http://cbio.mskcc.org/public/lung_array_data/ (35). CEL files from individual patients were converted into a single expression matrix using ExpressionFileCreator (v12.3, method=MAS5), followed by quantile normalization using the array NCI_U133A_61L as a reference as described before (34) . Probes were collapsed to gene symbols by selecting the probe with maximum mean expression after excluding probes mapping to multiple gene symbols (82) . From the list of differentially expressed genes (table S4) between T-SiglecF high and T-SiglecF low neutrophils, we selected genes with a minimum expression of 50 transcripts per million and > 5 times higher expression in T-SiglecF high neutrophils. The resulting 305 mouse genes were mapped to human orthologs using the HCOP tool (www. genenames.org/cgi-bin/hcop), including orthology predictions from Ensembl, NCBI, HGNC, Panther, HomoloGene, OrthoDB, OrthoMCL, OMA, PhylomeDB, TreeFam, Inparanoid, EggNOG. All orthologs were included for mouse genes mapping to multiple human genes. The conversion yielded 302 human orthologs (table S6) . Using human patient microarray data, each patient was attributed a 'T-SiglecF high neutrophil signature' value, defined as the sum rank transformed expression of the 302 human orthologs of genes enriched in T-SiglecF high neutrophils in mouse. Here, rank transformation refers to the process by which the expression of gene i in patient j in the microarray data is replaced with the rank for patient j among other patients based on the expression of i (dense ranking). The signature was rescaled to have values from 0 to 1. Cox regression analysis was performed using the T-SiglecF high neutrophil signature, sex, age, T stage, and N stage as predictor variables. Other sample characteristics, which were not documented for a fraction of patients, were used as strata; these included M stage, source of data, histological grade, smoking history, treatment with adjuvant chemotherapy and radiotherapy, tumor relapse, and positive surgical margin (table S7). All predictor variables satisfied the proportional hazards assumption as validated by a Schoenfeld residual tests (cox.zph function in R). To further validate the statistically significant p-value returned by the Cox Hazard test (p value = 0.0017), we randomly sampled 302 genes present in the microarray data, and recorded the number of times a Cox p-value smaller than the one observed was obtained. If the Cox Hazard model is accurate, we would expect approximately 0.17% of random trials to give the observed p-value or less. 7 out 1000 random samplings (0.7%) yielded a Cox p-value <0.0017, indicating a slight underestimate of the p-value by the Cox Hazard model, but nonetheless allowing to reject the null hypothesis of the gene selection being random with p < 0.01. The T-SiglecF low gene signature was defined in an analogous way, using the same number (n = 302) of human orthologs of genes most enriched in T-SiglecF low neutrophils. T-SiglecF low neutrophil gene signature showed no significant association with survival. For Kaplan-Meier plots, survival data of top 25% and bottom 25% SiglecF high or SiglecF low signature expressers was used. Survival analysis was performed using the "survival" package in R (83) and "Lifelines" package in Python (84) .
In vivo cell fate mapping
To track the progeny of hematopoietic precursors in tumor-bearing control or Ocn depleted mice, we performed cell fate mapping experiments. We used bead enrichment (Miltenyi 
Ex vivo ROS activity assay
Neutrophils were analyzed ex vivo for their reactive oxygen species (ROS) content. Single cell suspensions were generated from KP tumorbearing lungs or lungs of tumor-free mice as described in the Flow cytometry methods section. Cells were resuspended in HBSS containing 0.1% BSA followed by FACS antibody surface marker staining for 30min on ice as detailed below. Then cells were washed and resuspended in PBS-EGG buffer (1 mM EDTA, 0.05% gelatin, 0.09% glucose) and 0.5 mM DHR123 probe (Thermo Fisher Scientific) was added for 30 min at 37°C. The reaction was stopped by moving the tubes to ice and washing the cells with PBS-EGG buffer. Cells were resuspended in PBS containing 0.1% BSA and activated rhodamine 123 signal (activated DHR 123) was analyzed in the FITC channel on a LSRII flow cytometer (BD) within 30 min. Hydrogen peroxide added to cells served as a positive control.
In vitro macrophage differentiation experiment
Monocytes and neutrophil were co-cultured to investigate if neutrophils can help to mature macrophages from their monocytic precursors. as detailed in the Flow cytometry methods section. Murine spleens were harvested from tumor-bearing mice and were used to enrich for monocytes. In detail, spleens were harvested, meshed through a 40 mm cell strainer and ACK lysed to remove erythrocytes. Splenic monocytes were enriched through a MACS based negative isolation protocol by incubating single cells with PE conjugated Abs specific for CD90.2, CD3, B220, CD19 and Ly-6G followed by anti-PE MACS beads. Both incubation steps were performed for 20min on ice. The negative isolation resulted in a 20-fold enrichment of monocytes based on flow cytometry measurements. This population likely also include myeloid precursors since these accumulate in spleens of tumor-bearing mice (8) . For the coculture, 4 × 10 4 monocytes and 8 × 10 4 neutrophils were incubated in Iscove's DMEM media supplemented with 10% FBS and 1% penicillin/ streptomycin in 96-well cell culture plates for 6 days. Monocytes only and monocytes together with CSF-1 (1 ml/ml) were used as controls. Cells were removed from the plate and investigated by flow cytometry for F4/80 and CD11b expression in order to assess myeloid cell differentiation.
In vitro alkaline phosphatase assay for osteoblastic colony formation
To study whether tumor derived circulating factors can affect the osteogenic potential, osteoblastic colony formation was investigated after addition of serum pooled from individual mice that were either tumor-bearing or tumor-free. In some experiments tumor-free serum with or without sRAGE was added. Long bones (femur and tibia) and vertebrae of tumor-free C57BL/6 mice were harvested and flushed. Single cell suspensions were generated using 70 mm cell strainer and red blood cells removed in a ACK lysis step. Cells were counted and resuspended (4 × 10 7 /ml) in osteogenic medium (DMEM supplemented with 10% FBS and 1% penicillin/streptomycin, 10 mM B-glycerophosphate and 50 mg/ml ascorbic acid). 4x10 6 cells were transferred to 6 well cell culture plates and 200 ml serum from tumor-bearing or tumor-free mice added. Medium was refreshed every second day and nonadherent cells were removed. Cells were fixed after 9-10 days by adding 4% PFA for 8 min followed by 2 washing steps with H 2 O and the alkaline phosphate substrate reaction (B5655, Sigma) according to manufactures procedure. As counter stain, Nucleofast Red (Polysciences, Inc) was used. The number of ALP positive colonies was evaluated by 2-3 independent persons in a blinded manner.
In vitro co-culture of hematopoietic precursors and bone marrow stromal cells +/− sRAGE
To test whether sRAGE altered neutrophil maturation from hematopoietic precursors via stromal cells, we performed co-culture experiments. In detail, 1 × 10 3 ST2 cells per well were cultured in 96 well plates for two days. Then, bone marrow was harvested from tumor-free mice and depleted of differentiated cells using negative MACS bead separation (Abs specific for B220, CD19, Ter119, CD11c, CD11b, NK1.1, Dx5, CD127, Ly-6G and CD90.2 were utilized). The flowthrough was collected. The following conditions were tested: ST2 cells, with or without 1 × 10 4 lineage negative bone marrow cells, and with increased doses of sRAGE (namely: no sRAGE, 0.01 mg/ml, 0.1 mg/ml, 1 mg/ml). Neutrophil maturation was evaluated after three days by staining for CD11b, Ly-6G and CXCR2 surface expression using flow cytometry (1).
p53 recombined PCR for tumor cell detection
Detection of p53 recombined locus (only present in KP tumor cells after exposure to Cre recombinase) was used to survey bone and marrow tissues for KP tumor cell metastases. In brief, DNA was extracted from bone marrow or calvarial bone (after digestion) using DNeasy blood and tissue kit (Qiagen) according to manufacturer's instructions. KP1.9 tumor cells were used as positive control. Different DNA concentrations from KP1.9 tumor cells were used to determine PCR detection limit to <10 cells (with the estimate of~6pg DNA/ cell). DNA was isolated from Gel PCR products from a primary PCR run. A second PCR amplification run on these DNA samples was performed to detect low levels of DNA in the isolated tissues. The following primers were used: A: 5′ CAC AAA AAC AGG TTA AAC CCA G 3′; B: 5′ AGC ACA TAG GAG GCA GAG AC 3′; C: 5′ GAA GAC AGA AAA GGG GAG GG 3′. Following bands were amplified: p53 recombined 1lox: 612bp, WT band: 288bp and a background band: 400bp.
Real-time PCR for analysis of blood samples
Neutrophils from the blood of KP lung tumorbearing or tumor-free mice were investigated in order to define whether these cells exhibited transcriptional characteristics of tumor-infiltrating SiglecF high cells outside the tumor microenvironment. Neutrophils were FACS sorted based on surface marker expression (CD45 + CD11b + Ly-6G + ) and RNA was isolated from the sorted cells using the RNeasy Micro Kit (Qiagen) according to manufactures procedures. Afterwards, cDNA was generated utilizing the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and Real time PCR assays performed using the TaqMan Fast Advanced MasterMix together with TaqMan probes at the 7500 Fast Real-Time PCR System (Applied Biosystems). b2-Microglobulin was used as a housekeeping gene.
Protein array
To investigate soluble factors in serum or plasma of KP and KP1.9 lung tumor-bearing or tumorfree control mice, a membrane-based sandwich immunoassay with 111 different cytokine and chemokine antibodies was performed using the Proteome Profiler Mouse XL Cytokine Array Kit (R&D Systems) according to manufactures procedures. The captured soluble factors were visualized in duplicate using a chemiluminescent detection readout with an exposure time of 3 min. The signal intensity from each protein spot on the array was quantified using the Microarray_ Profile plugin in FIJI (www.optinav.info/MicroArray_ Profile.htm). The intensity was normalized against six reference spots on each array. From two independent experiments, fold change of tumor versus tumor-free soluble factors was calculated and the resulting values presented in a heat map. Factors below detection level and that failed to alter reproducibly were excluded from further analysis.
sRAGE ELISA
Mouse sRAGE levels in the serum of KP1.9 tumorbearing or tumor-free mice were quantified using ELISA according to manufacturer's instructions (MRG00, R&D systems). OD values were measured at 450 and 570nm (reference value) using a Tecan microplate reader. Murine blood was harvested and transferred to BD Microtainer tubes, incubated at room temperature for 30 min, spun at 1000 g for 15 min and the serum was stored at −80°C until ELISA analysis. The concentration of sRAGE in serum samples, investigated in duplicate, was calculated by extrapolating values of a standard curve following manufactures guidelines.
Flow cytometry
Single cell suspensions were obtained from lung tumors, bone marrow, spleen and bone tissue. The respective tissues and isolated single cell fractions were kept on ice for all steps if not stated otherwise. Tumor tissue was received by dissecting out tumor-bearing lungs. Small tissue pieces were generated using scissors and digested (RPMI containing 0.2 mg/ml collagenase type I, Worthington Biochemical Corporation) for 1 h at 37°C while shaking. Femurs and for some experiments tibias were harvested, cleaned and the bone marrow flushed out using cold staining buffer (PBS containing 0.5% BSA and 2 mM EDTA). Digested lung tissue and harvested bone marrow were gently meshed through 40 mM cell strainers using a plunger. Spleens were harvested and also meshed through 40 mM cell strainer as described before. Red blood cells were removed using 1 ml ACK lysis buffer (Lonza) per cell pellet for 1 min (for lung cells) or 2 min (for spleen cells) and the reaction was stopped with RPMI media. In some experiments blood was collected from the cheek or if mice were euthanized via cardiac puncture and directly treated with 5 ml ACK lysis buffer for 5 min to remove red blood cells. The resulting single-cell suspensions were washed and resuspended in staining buffer. In order to investigate bone cells by flow cytometry, in general, long bones were harvested, cleaned and crushed gently and the released cells were collected (fraction 1) and lysed with ACK lysis buffer. In parallel, the bone fragments (fraction 2) were cut into small pieces with scissors, filtered through 70 mM cell strainer, digested (PBS containing 20% FBS and 0.25% collagenase type I) for 1 h at 37°C, washed and finally pooled with the cells derived from fraction 1.
Single cell suspensions were incubated with FcBlock (clone 93, Biolegend) for 15 min at 4°C, followed by staining with fluorescent conjugated Abs for 45 min at 4°C. The cells were washed with staining buffer and analyzed on a LSRII flow cytometer (BD). 7-aminoactinomycin (7AAD, Sigma) positivity was used to exclude dead cells. 
Statistical methods
Unpaired t-test was used to compare two groups. Multiple t-test was performed to compare several cell populations between two groups and false discovery rate was accounted for using the Benjamini-Hochberg-Yekutieli procedure with Q = 1%. One-way or Two-way ANOVA with subsequent post-hoc analysis was done to compare three or more groups. GraphPad Prism was used to test for statistical significance except for when noted. Matlab and Python were used for scRNA-seq analysis, corresponding statistical testing is described above in section 'Neutrophil single cell RNA-seq'. Python was used for patient survival analysis as detailed in section 'Bioinformatical analyses of lung adenocarcinoma patients'. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s. not significant.
